Intel stock spikes after report of possible US government stake
Alexander O. Schuth, Chief Financial Officer and Secretary of Denali Therapeutics Inc. (NASDAQ:DNLI), sold 2,937 shares of the company’s common stock on August 12, 2025. The shares were sold at a weighted average price ranging from $13.35 to $13.58, generating total proceeds of $39884.
The transaction was executed to cover tax obligations related to the settlement of previously vested restricted stock units. Following the sale, Schuth directly owns 242,346 shares of Denali Therapeutics , including 128,405 unvested restricted stock units and 975 shares acquired through the Employee Stock Purchase Plan on June 2, 2025. InvestingPro data shows the company maintains strong liquidity with a current ratio of 10.27 and minimal leverage, with total debt to capital at just 0.02.
Schuth also indirectly owns 523,749 shares through The Schuth Family Trust U/A DTD 06/05/2017, for which he serves as trustee. While the company holds more cash than debt on its balance sheet, InvestingPro analysis indicates a rapid cash burn rate, with the company not yet achieving profitability in the last twelve months.
In other recent news, Denali Therapeutics Inc. has made significant strides with its Hunter syndrome treatment, as the U.S. Food and Drug Administration (FDA) accepted its Biologics License Application (BLA) for DNL310 with priority review. The FDA has set a target action date of January 5, 2026, for a potential approval decision. This development has been met with positive reactions from analysts, with Stifel maintaining a Buy rating and a $37.00 price target for Denali Therapeutics. Similarly, William Blair reiterated its Outperform rating, highlighting the breakthrough therapy designation as a key factor in the treatment’s accelerated approval process.
Denali’s innovative blood-brain barrier (BBB) shuttle technology has also attracted attention, with BTIG reiterating a Buy rating and a $32.00 price target. The company’s DNL310 has demonstrated a dosing capacity significantly higher than JCR’s approved version of iduronate 2-sulfatase, without causing unacceptable anemia. Additionally, Denali’s management has expressed confidence in their regulatory processes and potential accelerated approval for their Sanfilippo syndrome treatment, DNL126. These recent developments underscore Denali Therapeutics’ ongoing efforts and progress in advancing treatments for rare genetic disorders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.